Agape ATP Corporation (ATPC) AI Stock Analysis
ATPC AI stock analysis summary
AI ResearchAgape ATP Corporation is a Malaysian wellness and healthcare advisory company with a market cap of $1.6M. The company generated trailing twelve-month revenue of $1.3M alongside an operating margin of -4023.8%. Performance has been severely pressured, with shares down 70.7% year-to-date as of October 16, 2026.
- Market cap
- $1.6M
- Revenue (TTM)
- $1.3M
- P/E
- —
- 1Y return
- — S&P 500 16.8%
- Avg. target
- —
Bull case
- Annual revenue showed a recovery in FY2025, expanding 15.2% to $1.5M.
- The balance sheet maintains a high current ratio of 8.45 alongside a low debt-to-equity ratio of 0.00 as of June 30, 2026.
- Gross margin remained above half of sales at 53.7% in FY2025 despite margin compression from prior years.
Bear case
- Cash reserves stood at just $45,480 on June 30, 2026, while the company burned -$2.4M in free cash flow during FY2025.
- Quarterly revenue dropped 93.4% year-over-year in the quarter ended June 30, 2026.
- Share price declined 70.7% year-to-date to $1.57 as of October 16, 2026, near its 52-week low of $1.55.
What Agape ATP does
Agape ATP Corporation is a Kuala Lumpur-based investment holding firm focused on distributing health and wellness products and providing healthcare advisory services in Malaysia. Established in 2016, the company operates three primary programs: ATP Zeta Health Program, eNERGeTIQUE, and BEAUNIQUE. Product offerings include nutritional supplements like ATP1s Survivor Select, ATP2 Energized Mineral Concentrate, and ATP3 Ionized Cal-Mag, which target metabolic functions. It also provides formulations like AGN-Vege Fruit Fiber, AGP1 Iron, and YFA-Young Formula, alongside skincare items such as BEAUNIQUE Mito+ and ORYC-Organic Youth Care Cleansing Bar. In addition, the firm engages in product wholesaling and complementary health therapies.
Growth and profitability
Over the past five fiscal years, revenue contracted at a CAGR of -15.1% between FY2020 and FY2025. Annual revenue grew 15.2% in FY2025 to $1.5M, rebounding slightly from $1.3M in FY2024, but gross margin decreased to 53.7% compared to 57.4% in FY2024 and 70.8% in FY2021. Operating losses remained significant, with FY2025 operating margin at -213.7% and net income at -$2.3M. For the trailing twelve months, revenue reached $1.3M with a net profit margin of -86.3% and EPS of -$1.04. In the latest quarter ended June 30, 2026, quarterly revenue fell 93.4% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Agape ATP held $45,480 in cash and short-term investments against total debt of $62,681, resulting in net debt of $17,201. The company reported shareholders' equity of $22.1M and total assets of $25.0M, supporting a current ratio of 8.45 and a debt-to-equity ratio of 0.00. Operating cash flow was negative at -$2.4M in FY2025, matching a free cash flow deficit of -$2.4M. Capital expenditures were $1,049 in FY2025, while the share count declined 86.7% over five years.
Valuation and performance
Agape ATP trades at a price-to-sales multiple of 1.2x and an enterprise value to revenue ratio of 1.7x, compared to the median of 0.7x price-to-sales for its US-listed Consumer Defensive peers. The stock's price-to-book ratio stands at 0.1x. As of October 16, 2026, shares closed at $1.57, down 70.7% year-to-date and 44.0% below the 200-day moving average. The stock trades near its 52-week low of $1.55 and well below its 52-week high of $56.50, while the S&P 500 benchmark registered a 1-year return of 16.8%.
What analysts expect
Wall Street analyst ratings and price targets are not currently available for Agape ATP Corporation. The company's next earnings date is scheduled for November 12, 2026. Institutional ownership accounts for 10.9% of outstanding shares, insiders hold 2.0%, and short interest represents 1.0% of the float.
Key risks and what to watch
- A cash balance of $45,480 leaves minimal liquidity given the FY2025 operating cash outflow of -$2.4M.
- Severe sales contraction reflected in the 93.4% quarterly revenue drop raises questions about commercial traction.
- A trailing twelve months operating margin of -4023.8% highlights high overhead relative to generated revenue.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ATPC AI stock analysis
This page is an AI-written research summary of Agape ATP Corporation (ATPC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ATPC income statement, ATPC balance sheet, ATPC key metrics, ATPC chart. See the ATPC stock overview for the latest quote and news.
ATPC AI stock analysis FAQ
What products does Agape ATP Corporation sell?
The company sells health and wellness products under the ATP Zeta Health Program, eNERGeTIQUE, and BEAUNIQUE lines. Products include supplements such as ATP1s Survivor Select and ATP2 Energized Mineral Concentrate, as well as skincare items like BEAUNIQUE Mito+.
Does Agape ATP Corporation pay a dividend?
No, Agape ATP Corporation does not currently pay a dividend to shareholders.
What is Agape ATP Corporation's cash and debt position?
As of June 30, 2026, the company held $45,480 in cash and short-term investments and $62,681 in total debt, yielding net debt of $17,201.
When is Agape ATP Corporation's next earnings report?
The company's next earnings release is scheduled for November 12, 2026.